Cumberland Pharmaceuticals, Inc. v. Mylan Institutional LLC
137 F. Supp. 3d 1108
N.D. Ill.2015Background
- Cumberland developed Acetadote (intravenous acetylcysteine) and obtained patents: the ’356 (composition) and the ’445 (methods). Cumberland later dropped the ’356 claims; dispute focuses on validity of the ’445 patent and Mylan’s ANDA for a generic EDTA‑free product.
- Leo Pavliv (Cumberland) is sole named inventor of the ’445 patent; he conceived studying removal/reduction of EDTA after FDA asked Cumberland (Dec. 2002) to justify EDTA’s inclusion in Acetadote.
- Cumberland proposed and agreed (post‑approval commitment) to conduct stability studies comparing current EDTA level, reduced EDTA, and no EDTA; Pavliv drafted the protocol, Bioniche ran the tests, and data (3‑ and 6‑month) showed no stability difference.
- Mylan filed an ANDA (Dec. 2011) with a Paragraph IV certification and was later sued by Cumberland for infringement; Mylan admitted infringement if the ’445 patent is valid but argued invalidity by derivation, anticipation, and obviousness.
- Trial court found Mylan failed to prove invalidity by clear and convincing evidence on all three grounds and entered judgment holding Mylan liable for infringement of the ’445 patent.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Derivation (35 U.S.C. § 102(f)) | Pavliv conceived the EDTA‑free formulation; he proposed and authored the post‑approval study and designed protocol. | FDA employees conceived the idea (through requests/communications) and communicated it to Cumberland. | Court held Mylan failed to prove conception by FDA; Pavliv was the sole conceiver. |
| Anticipation (35 U.S.C. § 102(b)) | Approval letter and package insert do not disclose every claim limitation (especially "free of chelating agents") and were not a single, enabling prior art reference. | FDA Approval Letter + Package Insert (and NDA materials) disclosed the claimed method/composition and the commitment to study EDTA removal. | Court held prior art did not anticipate: documents were not a single incorporated reference and did not enable all claim limitations. |
| Obviousness (35 U.S.C. § 103) | The claimed EDTA‑free formulation and method were nonobvious given unpredictability of pharmaceutical stability; objective indicia (unexpected results) support validity. | Prior art (e.g., Waterman, other patents, FDA materials) would have motivated a skilled artisan to remove EDTA; removal was obvious. | Court held Mylan did not meet clear and convincing standard for obviousness: prior art taught use of chelators and did not make EDTA removal predictable. |
| Remedy / Infringement posture | Cumberland sought enforcement of ’445 patent; Mylan stipulated to infringement if patent valid. | Mylan relied on invalidity defenses to avoid liability. | Because invalidity defenses failed, court entered judgment for Cumberland on infringement. |
Key Cases Cited
- Microsoft Corp. v. 141 Ltd. Partnership, 564 U.S. 91 (legal standard on clear and convincing burden and deference to PTO)
- Sciele Pharma Inc. v. Lupin Ltd., 684 F.3d 1253 (Fed. Cir. 2012) (deference to PTO and burden of proof)
- Burroughs Wellcome Co. v. Barr Labs., Inc., 40 F.3d 1223 (Fed. Cir. 1994) (conception doctrine; simultaneous conception and reduction to practice)
- Price v. Symsek, 988 F.2d 1187 (Fed. Cir. 1993) (elements of derivation)
- In re Omeprazole Patent Litigation, 483 F.3d 1364 (Fed. Cir. 2007) (anticipation requires every claim limitation in a single reference)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (obviousness framework; caution against hindsight)
- Graham v. John Deere Co. of Kansas City, 383 U.S. 1 (1966) (framework for obviousness and secondary considerations)
- Allergan, Inc. v. Apotex Inc., 754 F.3d 952 (Fed. Cir. 2014) (skepticism of sole‑inventor oral testimony without corroboration)